Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CR-001 · 1 trial · 1 indication
Per cohort
Per Cohort
Events graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)
| Arm | Type | Description |
|---|---|---|
| CR-001 Dose escalation | EXPERIMENTAL | Escalating dose levels of CR-001 to define the maximum tolerated dose of CR-001 in participants with locally advanced or metastatic solid tumors who are refractory to or unable to tolerate standard of care treatment, or for whom standard of care treatment is unavailable |
| CR-001 Backfill | EXPERIMENTAL | Escalating dose levels of CR-001 Indication-specific cohort populations will be tested |
| CR-001 Dose Expansion 3A: First-line (1L) Non-small cell lung cancer | EXPERIMENTAL | CR-001 in combination with paclitaxel or pemetrexed + carboplatin |
| CR-001 Dose Expansion 3B: First-line (1L) colorectal cancer | EXPERIMENTAL | CR-001 in combination with FOLFOX |
| CR-001 Dose Expansion 3C: Third-line (3L) colorectal cancer | EXPERIMENTAL | CR-001 in combination with trifluridine + tipiracil |
| CR-001 Dose Expansion 3D: First-line (1L) endometrial carcinoma | EXPERIMENTAL | CR-001 in combination with paclitaxel + carboplatin |
| CR-001 Dose Expansion 3E: First-line (1L) gastric/gastroesophageal cancer | EXPERIMENTAL | CR-001 in combination capecitabine + oxaliplatin |
| CR-001 Dose Expansion 3F: Second-line (2L) gastric/gastroesophageal cancer | EXPERIMENTAL | CR-001 in combination with paclitaxel |
| CR-001 Dose Expansion 3G: First-line (1L) Biliary tract cancer | EXPERIMENTAL | CR-001 in combination with gemcitabine + cisplatin |
| CR-001 Dose Optimization Cohort X | EXPERIMENTAL | monotherapy dose level (DL)-X Indication-specific cohort populations will be tested |
| CR-001 Dose Optimization Cohort Y | EXPERIMENTAL | monotherapy dose level (DL)-Y Indication-specific cohort populations will be tested |
| Name | Type | Description |
|---|---|---|
| CR-001 | DRUG | Intravenous Infusion |
| Paclitaxel | DRUG | Intravenous Infusion |
| trifluridine and tipiracil | DRUG | Oral |
| Pemetrexed | DRUG | Intravenous Infusion |
| Carboplatin | DRUG | Intravenous Infusion |
| Oxaliplatin | DRUG | Intravenous Infusion |
| Gemcitabin | DRUG | Intravenous Infusion |
| Cisplatin | DRUG | Intravenous Infusion |
| Capecitabine | DRUG | Oral |
| FOLFOX | DRUG | Intravenous Infusion + Oral |
Key Inclusion Criteria * Life expectancy ≥ 3 months * Eastern Cooperative Oncology Group (ECOG) performance status score of 0 - 1 * Adequate organ function and hematologic reserve based on laboratory parameters * Have measurable disease defined by RECIST v1.1 * For Backfill, Dose Expansion and Dose...
CR-001 is an investigational biologic developed by Crescent Biopharma, Inc. for locally advanced or metastatic solid tumors. It is in Phase 1/2 clinical development in oncology and is being studied in adult participants with advanced solid tumors across multiple countries.
CR-001 is being studied for the treatment of locally advanced or metastatic solid tumors. It is an oncology asset in Phase 1/2 development and is not yet established as a treatment outside clinical research. The ongoing study enrolls adults aged 18 years and older.
CR-001 targets PD-1, a protein target. PD-1 is a checkpoint receptor on immune cells, and agents directed at it are designed to act on PD-1 mediated signaling. CR-001 is a biologic in Phase 1/2 development for locally advanced or metastatic solid tumors.
CR-001 is being developed by Crescent Biopharma, Inc., which trades under the ticker CBIO. The company is running the Phase 1/2 program in locally advanced or metastatic solid tumors, with the study currently recruiting participants across the United States, Europe, Australia, and South Korea.
CR-001 is in Phase 1/2 clinical development. It is an investigational agent and is not described as FDA approved. The single ongoing trial is a Phase 1/Phase 2 study that is currently recruiting, with planned enrollment of 540 participants.
CR-001 is being studied in trial NCT07335497, titled CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors. The Phase 1/Phase 2 study is recruiting, is controlled, is not randomized or double blinded, and plans to enroll 540 adults across ten countries.
Yes, CR-001 is also known as 001. Both names refer to the same investigational biologic from Crescent Biopharma, Inc. (ticker CBIO) that targets PD-1 and is in Phase 1/2 development for locally advanced or metastatic solid tumors.